[Extracorporeal systemic hyperthermia and cis-diamminedichloroplatinum for treatment of patients with advanced cancer].
Extracorporeal systemic hyperthermia was effective in removing pleural effusion or ascites and for pain relief in patients with advanced cancer. The administration of cisplatin was combined with hyperthermia. Partial remission was noted in 18% of the cases. With the use of cisplatin dosage over 1 mg/kg, approximately 50% of cases showed effective results. Cisplatin dosage should be 1.6mg/kg or more when combined with hyperthermia. Renal failure was the most common complication.
D001831:Body Temperature; D001943:Breast Neoplasms / Q000188:drug therapy / Q000628:therapy; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000628:therapy; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods*; D008175:Lung Neoplasms / Q000188:drug therapy / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy / Q000628:therapy*; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000628:therapy; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000628:therapy
D002945:Cisplatin